Epithelial cell adhesion molecule (EpCAM) binding short peptides derived from antibody MOC-31; De-novo design, synthesis and their in-vitro evaluation.

Autor: Shinde SD; National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat, 380054, India., Rao KB; National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat, 380054, India., Behera SK; National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat, 380054, India., Arya N; National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat, 380054, India., Sahu B; National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat, 380054, India. Electronic address: bichismita77@gmail.com.
Jazyk: angličtina
Zdroj: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2022 Apr 16; Vol. 600, pp. 1-5. Date of Electronic Publication: 2022 Feb 08.
DOI: 10.1016/j.bbrc.2022.01.120
Abstrakt: Epithelial cell adhesion molecule (EpCAM) is one of the critical bio-maker for circulating tumor cells (CTC) detection. For capturing CTC, antibody-antigen-based techniques have mainly been explored. However, the expensiveness and tedious manufacturing process have posed certain limitations for antibody-based techniques for its wide applications in cell capturing. On the other hand, peptides are inexpensive bimolecular probes with high specificity and tunability. Although there are few reports on EpCAM binding peptides are available in literature, those peptides were selected through random library screening. Interestingly, de-novo design of the peptides against EpCAM has not been reported till date. For the first time, we have developed a small peptide (Pep14) from the complementary derived region (CDRs) of antibody MOC31 through systematic virtual screening. Selected peptide has demonstrated good binding affinity towards EpCAM with dissociation constant (Kd) of 870 nM and found to be co-localized with the anti-EpCAM antibody in EpCAM expressing cancer cells (MCF-7). Therefore, the short peptide Pep14 hold promise for capturing circulatory tumor cells through EpCAM binding.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: